The Ohio State University was awarded a $971,401 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct tissue engineering research for cutaneous and systemic epidermolysis bullosa gene therapy. The project will run from September 1, 2023 to August 31, 2026. Epidermolysis bullosa is a rare genetic condition that causes fragile, blistering skin. This research aims to develop innovative gene therapy treatments to address this debilitating disease.
Generated 5/7/24, 8:50 AM